This site is intended only for Australian Healthcare Professionals
Menu
Close
Menu
Close
AS=ankylosing spondylitis; TB=tuberculosis.
See the XELJANZ safety data for AS
Want to see pivotal data in active AS?
▼This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.
WARNINGS XELJANZ should only be used if no suitable treatment alternatives are available in patients:
See PI for details, Section 4.4 Special Warnings and Precautions for Use: Mortality; Major Adverse Cardiovascular Events (including Myocardial Infarction); Thrombosis; Malignancy and Lymphoproliferative Disorder (excluding Nonmelanoma Skin Cancer [NMSC]); Skin Cancer and Use in the Elderly. |
Before prescribing, please review full Product Information available here.
PBS Information: Authority required. Refer to PBS Schedule for full authority information.
®Registered Trademark.
PP-XEL-AUS-1429 11/23.
To access further materials, resources and receive communication about Pfizer medicines and vaccines.
The site is intended for Australian healthcare professionals.
©2023 Pfizer Australia Pty Ltd. Sydney, Australia. All rights reserved.
PP-UNP-AUS-0551 12/23.